Evidence map›Paper›PMID 28153092›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017

GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration.

Jiusheng Deng, Yanqiu Li, Andrea Pennati, Shala Yuan, Jian Hui Wu, Edmund K Waller, Jacques Galipeau

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiusheng DengDivision of Bone Marrow Transplantation and Immunotherapy, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. Electronic address: jdeng2@emory.edu.
Yanqiu LiDivision of Bone Marrow Transplantation and Immunotherapy, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Andrea PennatiDivision of Bone Marrow Transplantation and Immunotherapy, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Shala YuanDivision of Bone Marrow Transplantation and Immunotherapy, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Jian Hui WuLady Davis Institute for Medical Research, Department of Oncology, McGill University, Montreal, QC H3A OG4, Canada.
Edmund K WallerDivision of Bone Marrow Transplantation and Immunotherapy, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Jacques GalipeauDivision of Bone Marrow Transplantation and Immunotherapy, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. Electronic address: jgalipe@emory.edu.

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Inducible B-regulatory cells (iBREGs) for treatment of Multiple SclerosisR01AI093881 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI GALIPEAU, JACQUES · 2012 to 2016
$1.9M
NCATS NIH HHS UL1 TR000454NCI NIH HHS P30 CA138292NIAID NIH HHS R01 AI093881
6 · The paper itself

Abstract

Hematopoietic stem cells (HSCs) have the capacity to self-renew and differentiate into hematopoietic cells and have been utilized to replace diseased bone marrow for patients with cancers and blood disorders. Although remarkable progress has been made in developing new tools to manipulate HSCs for clinic use, there is still no effective method to expand HSCs in vivo for quick repopulation of hematopoietic cells following sublethal irradiation. We have recently described a novel synthetic cytokine that is derived from the fusion of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4; named as GIFT4), and we have now discovered that GIFT4 fusokine promotes long-term hematopoietic regeneration in a B cell-dependent manner. We found that GIFT4 treatment triggered a robust expansion of endogenous bone marrow HSCs and multipotent progenitors in vivo. Delivery of GIFT4 protein together with B cells rescued lethally irradiated mice. Moreover, adoptive transfer of autologous or allogeneic GIFT4-treated B cells (GIFT4-B cells) enhanced long-term hematopoietic recovery in radiated mice and prevented the mice from irradiation-induced death. Our data suggest that GIFT4 as well as GIFT4-B cells could serve as means to augment HSC engraftment in the setting of bone marrow transplantation for patients with hematological malignancy.

Indexed as

Granulocyte-Macrophage Colony-Stimulating FactorInterleukin-4AnimalsBiomarkersB-LymphocytesBone Marrow CellsCell DifferentiationCell ProliferationCytokinesHematopoietic Stem CellsImmunophenotypingLymphopoiesisMaleMiceModels, AnimalPhenotypeBiomarkersCytokinesGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-4Recombinant Fusion ProteinsB cellsfusion cytokinehematopoietic stem cells

Identifiers

PMID28153092
PMCPMC5368424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.